Structure via PubChem · Public domain (PubChem)
pimozide
Also known as haldol decanoate, Orap®, R-6238, Pimozidum, Pimozida
Pimozide (sold under the brand name Orap) is a neuroleptic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special indication for Tourette syndrome and resistant tics.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464206733
- Drug.IUPAC_name
- 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazole-2-one
- Drug.image
- Pimozide.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- Pimozide-based-on-xtal-3D-bs-17.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Orap
- Drug.MedlinePlus
- a686018
- Drug.licence_US
- Pimozide
- Drug.pregnancy_AU
- B1
~6 min read
Article
11 sectionsContents
- Medical uses
- Efficacy
- Contraindications
- Side effects
- Overdose
- Pharmacology
- History
- See also
- Notes
- References
- External links
Pimozide (sold under the brand name Orap) is a neuroleptic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special indication for Tourette syndrome and resistant tics.
== Medical uses ==